RFK Jr. takes shortcut to make some peptides more widely available

Read the original at NBC News ↗
Cite

Jr., B. L. (2026, October 28). RFK Jr. takes shortcut to make some peptides more widely available. NBC News. https://www.nbcnews.com/health/health-news/rfk-jr-takes-shortcut-make-peptides-widely-available-rcna606133

Dated from the outlet's own feed. Check the original for its byline.

NBC News · collected 2026-10-28 · by Berkeley Lovelace Jr.

Quick Summary

The Department of Health and Human Services has temporarily allowed compounding pharmacies to manufacture six unapproved peptides without legal repercussions while the FDA formalizes new rules for their production. These peptides include BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500, which are marketed as treatments for various health conditions but lack FDA approval due to insufficient safety and efficacy data. The move aims to shift consumers from the current "gray market" of peptides labeled as research-only products towards regulated compounding pharmacies, though critics argue this undermines drug regulation standards.
Written by AI on 2026-10-29, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Robert F. Kennedy Jr., the U.S. Health Secretary, pushed for a plan to allow easier access to unapproved peptide drugs, despite opposition from FDA scientific staff who warned it could compromise public safety. The policy, published on October 28, instructs the FDA not to take legal action against compounding pharmacies that produce six specific peptides—BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500—even though these substances have not undergone rigorous safety reviews. The FDA staff had limited input in drafting this policy, which is now under regulatory review at the White House before final publication. Critics, including experts from the Partnership for Safe Medicines, argue that allowing access to untested peptides could expose Americans to dangerous health risks and undermine the FDA's mission of ensuring product safety.

Written for “FDA Scientists Oppose Peptide Access Ease” on 2026-10-29, grounded in this article and the 3 other(s) covering the same event.
Why this leaning score
The model judged this article politically coded and scored it -0.35, but all 3 of its quote(s) are attributed speech - words the article quotes from someone, not the article's own narration, so the score is not published.
Written under an earlier scoring contract, which gave a paragraph rather than checkable quotes. Re-analysing this article replaces it.
Leaning score withheld for article 112426: attributed speech only · logged 2026-10-29

Story

📰 FDA Scientists Oppose Peptide Access Ease
Health · 4 article(s) covering the same event. See how they differ ↓

Compared with similar articles

This article reads unscored and hedges 21% of its claims. Each row says how that neighbour differs.
Toronto Star
⚖️ Leans left Hedges 5 of 33 claims Outlet record 64/100
The Guardian
⚖️ Leans left Hedges 4 of 30 claims Outlet record 67/100
TIME
Hedges 3 of 28 claims Outlet record 59/100
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
19
sentences that state something as happening or true
Uncertain
21%
4 of 19 hedged ("reportedly", "may", "according to")
Leaning
withheld
no quote in the article backed the model's score
Publisher signals
95/100
NBC News's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
4
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-29 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

NBC News · 1845 article(s) · 0 correction(s) detected
No corrections detected for this publisher. That may mean careful reporting, or simply that nothing has been checked.

Who wrote this

Berkeley Lovelace Jr.
7 article(s) here · 1 carrying a prediction
🔮 In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides.
🔮 Researchers focused on those drugs because patients don’t have the option of switching to cheaper versions, meaning the discounts offered through TrumpRx could have a greater impact on what they pay.
🔮 She added, however, that retatrutide “may be too strong for some patients,” particularly those with only mild diabetes or slightly elevated weight.
🔮 Dr. Heidi Overton, a fierce opponent of abortion rights, is set to appear before senators Thursday for her confirmation hearing to lead the Food and Drug Administration.
🔮 The cuts, Vance said, would save U.S. taxpayers $2.2 billion.
🔮 It’s too early to predict how severe the upcoming flu season will be and the Centers for Disease Control and Prevention hasn’t started tracking cases yet.
🔮 In some cases, the premium increases may be the largest in decades and are driven by numerous economic pressures.
2026-09-13 · mixed framing · Your health insurance bills are about to go up
Also by Berkeley Lovelace Jr.
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 7 articles by Berkeley Lovelace Jr. →

Topics

FDA HHS The Department of Health and Human Services semax the Food and Drug Administration’s

Subjects

FDA ORG · 9× HHS ORG · 2× Emily Hilliard PERSON · 1× Health ORG · 1× Peter Lurie PERSON · 1× Robert F. Kennedy Jr. PERSON · 1× The Department of Health and Human Services ORG · 1× Trump PERSON · 1× the Center for Science in the Public Interest ORG · 1× the Food and Drug Administration’s ORG · 1×

Narrative

Shabbir Safdar, executive director of the Partnership for Safe Medicines, which researches the dangers of counterfeit medicines, said both the enforcement discretion and upcoming rule change would expose Americans to “untested dangerous substances.”
framing: mixed · carried by 1 article(s) · first seen 2026-10-29
🔮 In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides.

Claims (19 extracted, 4 hedged)

The Department of Health and Human Services is giving compounding pharmacies a temporary green light to make six peptides while the agency continues to work on a formal rule change. asserted
agency → give → change
In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides. asserted
that → file → peptides
In practice, that means these pharmacies can start offering them now, even though the peptides aren’t yet on the Food and Drug Administration’s list of ingredients compounding pharmacies are allowed to make. asserted
pharmacies → mean → ingredients
They’ve been promoted online as treatments for everything from faster healing to younger-looking skin and a longer lifespan. asserted
They → promote → skin
None are approved by the FDA, and the agency’s own scientists concluded there is insufficient data to prove they are safe and effective. asserted
they → approve → FDA
The FDA said compounding pharmacies must certify the identity and purity of the compounds. asserted
pharmacies → say → compounds
They must also now report side effects, which was not previously mandated. asserted
which → report → effects
The move comes as a growing “gray market” has sprung up around peptides, where retailers sell them labeled “for research use only,” a legal workaround that lets them claim they aren’t meant for humans. uncertain
they → come → humans
Health Secretary Robert F. Kennedy Jr. and others have argued that allowing peptides to be compounded would move people away from this gray market and toward safer products. asserted
peptides → argue → products
“Under President Trump’s leadership, HHS is working to put prevention and patient safety at the center of health care—and that includes confronting the risks of black-market peptides,” Emily Hilliard, an HHS spokesperson, said in a statement. asserted
Hilliard → work → statement
Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest watchdog group, said the FDA was essentially “turning a blind eye” to widen access to drugs that have not been proven to work. asserted
that → lead → drugs
Compounding pharmacies generally may use only ingredients the FDA has added to an official list known as the bulk drugs substances list. uncertain
FDA → compound → list
Adding an ingredient requires the FDA to propose a rule, take public comment and issue a final rule, a process that can take several months. asserted
that → add → months
The agency took a step toward that process in July, when an FDA advisory panel narrowly voted in favor of adding six peptides to the bulk list. asserted
panel → take → list
The panel included six new appointees with ties to the peptide industry and another who is the son of a U.S. representative who has pushed Kennedy to make peptides more available. asserted
peptides → include → Kennedy
(During that meeting, some committee members expressed concerns that the recommendation could make it harder for the FDA to say no to other unapproved drugs in the future.) uncertain
FDA → express → future
On Tuesday and Wednesday, the FDA was scheduled to meet outside groups, including Medivant Healthcare, a compounding pharmacy that offers peptides, according to Reginfo.gov, a federal website that tracks government regulations. uncertain
that → schedule → regulations
Shabbir Safdar, executive director of the Partnership for Safe Medicines, which researches the dangers of counterfeit medicines, said both the enforcement discretion and upcoming rule change would expose Americans to “untested dangerous substances.” asserted
discretion → research → substances
“Imagine what it means for the nation’s top drug regulator to announce they won’t enforce the laws on people making completely untested compounds and distributing them to the public,” Safdar said. asserted
Safdar → imagine → public
💬Give feedback
🕘History 🎫Support